Abstract:Background and purpose:Promoter methylation ofPCDH10, a gene encoding protocadherin 10, has been found to be correlated to poor prognosis in gastric cancer (GC) patients. However, the relationship between the expression of PCDH10 and prognosis in GC remained unknown. This study aimed to explore the relationship be-tween the expression of PCDH10 and clinicopathological features and prognosis of GC, and to identify biomarker for predictions of recurrence and survival of GC.Methods:mRNA expressions of PCDH10 in 115 pairs of GC tissues and adjacent normal tissues were detected by real-time lfuorescence quantitative polymerase chain reaction (RTFQ-PCR). The correlation between PCDH10 expression level and clinicopathological features and prognosis of GC was analyzed. Prediction models for 5-year recurrence and 5-year survival were established using logistic regression method.Results:Progression-free survival (PFS) and overall survival (OS) were signiifcantly prolonged in patients with PCDH10 low expression compared to patients without PCDH10 low expression (P=0.046 andP=0.033 respectively). PCDH10 low expression signiifcantly correlated with less lymph node metastasis (P=0.001) and earlier TNM staging (P=0.001), and was more common in female than in male (P=0.040). The mRNA expression of PCDH10 did not correlate with age, Lauren classiifcation, T stage, neural invasion or vascular invasion. Univariate Cox analysis showed Lauren classiifca-tion, T stage, N stage, M stage and PCDH10 expression signiifcantly correlated with PFS and OS. Logistic regression models for the prediction of 5-year recurrence or 5-year survival based on clinicopathological features included Lauren classiifcation, T stage, N stage and M stage as variables. Logistic regression models for the prediction of 5-year recur-rence or 5-year survival based on PCDH10 expression included Lauren classiifcation, T stage, M stage and PCDH10 expression level but not N stage as variables. The models based on PCDH10 expression had the same effciencies as models based on clinical parameters in predicting 5-year recurrence or 5-year survival for GC patients.Conclusion:PCDH10 low expression correlated with better prognosis, less lymph node metastasis and earlier TNM stage in GC patients. Low expression of PCDH10 may be a biomarker of better survival for GC patients. Logistic regression model based on PCDH10 mRNA expression may serve as a prediction model when patients have unknown lymph node metas-tasis status.

PCDH20 acts as a tumour-suppressor gene through the Wnt/β-catenin signalling pathway in hypopharyngeal squamous cell carcinoma

PCDH20 functions as a tumour-suppressor gene through antagonizing the Wnt/β-catenin signalling pathway in hepatocellular carcinoma.

Protocadherin-1 Serves As a Prognostic Biomarker and Promotes Pancreatic Cancer Progression by Suppressing CD8+ T Cell Infiltration Through CCL5-CCR5 Axis.

PCDH20 inhibits esophageal squamous cell carcinoma proliferation and migration by suppression of the mitogen-activated protein kinase 9/AKT/β-catenin pathway

Down-regulated of PCDH10 predicts poor prognosis in hepatocellular carcinoma patients.

Protocadherin 17 Acts As a Tumour Suppressor Inducing Tumour Cell Apoptosis and Autophagy, and is Frequently Methylated in Gastric and Colorectal Cancers

Methylation of PCDH19 Predicts Poor Prognosis of Hepatocellular Carcinoma.

Differential prognostic impact and potential molecular mechanisms of PCDHGA12 expression in lung adenocarcinoma and squamous cell carcinoma

Protocadherin20 Acts As a Tumor Suppressor Gene: Epigenetic Inactivation in Nasopharyngeal Carcinoma.

Comprehensive analysis reveals CCDC60 as a potential biomarker correlated with prognosis and immune infiltration of head and neck squamous cell carcinoma

Loss of PCDH9 is associated with the differentiation of tumor cells and metastasis and predicts poor survival in gastric cancer

Cell division cycle-associated 8 is a prognostic biomarker related to immune invasion in hepatocellular carcinoma

PHGDH promotes esophageal squamous cell carcinoma progression via Wnt/β-catenin pathway

PCDH8 is a novel prognostic biomarker in thyroid cancer and promotes cell proliferation and viability

The Human Homolog of Drosophila Headcase Acts As A Tumor Suppressor Through Its Blocking Effect on the Cell Cycle in Hepatocellular Carcinoma

Pcdh9 Acts As A Tumor Suppressor Inducing Tumor Cell Arrest at G(0)/G(1) Phase and is Frequently Methylated in Hepatocellular Carcinoma

X-linked FHL1 As a Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

Epigenetic Inactivation of PCDH10 in Human Prostate Cancer Cell Lines

Correlation between mRNA expression of protocadherin-10 and prognosis in gastric cancer

Parathyroid hormone-related protein serves as a prognostic indicator in oral squamous cell carcinoma

PCDHGA10 as a Potential Biomarker of Lung Squamous Cell Carcinoma Based on Bioinformatics and Experimental Verification